Please ensure Javascript is enabled for purposes of website accessibility

Why MannKind Shares Are Soaring Again Today

By Keith Speights – Jun 17, 2020 at 11:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Momentum is still in swing from the biotech's recent presentations.

What happened

Shares of MannKind Corporation (NASDAQ: MNKD) were soaring 16.7% higher as of 11:13 a.m. EDT on Wednesday. This marked the second day of double-digit-percentage gains this week following the company's presentation of new positive data from clinical studies for Afrezza at the American Diabetes Association's 80th Scientific Sessions conference.

So what

To be sure, MannKind's ADA presentations were good news. The more data the company gathers on Afrezza, the more attractive the inhaled insulin product looks for physicians and patients. It's not all that surprising that the momentum for the biotech stock would extend over multiple days.

Hands holding Afrezza inhaler

Image source: MannKind Corporation. 

There's also potentially another factor at play, though. MannKind entered into June with around 14% of its outstanding shares sold short. The big jump for the stock on Monday could have caused some of those short-sellers to cover their positions and continue doing so today. 

When this scenario unfolds, it can create buying pressure that drives shares up even more than they otherwise would rise. It's too soon to know if there's really a full-fledged short squeeze in progress for MannKind, but it's certainly possible that's what is happening.

Now what

MannKind's positive stock momentum and well-received ADA presentations are great. However, the important thing for investors to watch with the company is how Afrezza performs in the marketplace. Sales for the drug continue to climb, but a lot more growth is needed before MannKind will be profitable.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.